Medulloblastoma is the most common malignant childhood brain tumor. The heterogeneous tumors are classified into four subgroups based on transcription profiles. Recent developments in genome-wide sequencing techniques have rapidly advanced the understanding of these tumors. The high percentages of somatic alterations of genes encoding chromatin regulators in all subgroups suggest that epigenetic deregulation is a major driver of medulloblastoma. In this report, we review the current understanding of epigenetic regulation in medulloblastoma with a focus on the functional studies of chromatin regulators in the initiation and progression of specific subgroups of medulloblastoma. We also discuss the potential usage of epigenetic inhibitors for medulloblastoma treatment.
A B S T R A C T
Medulloblastoma is the most common malignant childhood brain tumor. The heterogeneous tumors are classified into four subgroups based on transcription profiles. Recent developments in genome-wide sequencing techniques have rapidly advanced the understanding of these tumors. The high percentages of somatic alterations of genes encoding chromatin regulators in all subgroups suggest that epigenetic deregulation is a major driver of medulloblastoma. In this report, we review the current understanding of epigenetic regulation in medulloblastoma with a focus on the functional studies of chromatin regulators in the initiation and progression of specific subgroups of medulloblastoma. We also discuss the potential usage of epigenetic inhibitors for medulloblastoma treatment.
Medulloblastoma subgroups
Medulloblastoma of the cerebellum accounts for 20% of malignant childhood brain tumors. These tumors mainly occur during infancy and childhood, but a small percentage occur in adulthood. The overall survival of medulloblastoma patients is relatively high due to efficacy of traditional radiation therapy and chemotherapy; however, the longterm effects of these treatments on development and cognition are debilitating (Gajjar et al., 2006; Northcott et al., 2012b; Rutkowski et al., 2010) . Recent genomic studies of medulloblastoma have dramatically improved our understanding of the genetic causes and molecular programs underlying progression of medulloblastoma (Gajjar et al., 2015; Holgado et al., 2017; Northcott et al., 2015) . The disease is heterogeneous and tumors are classified into four subgroups based on distinctive transcription profiles. These subgroups are referred to as WNT, SHH, Group 3, and Group 4 Northcott et al., 2012c; Parsons et al., 2011; Pugh et al., 2012; Robinson et al., 2012) . Subgroups differ in age and gender distributions and clinical outcomes. At the molecular level, the tumors from the different subgroups are characterized by specific mutations, rely on distinct signaling pathways, and possibly have different cell origins Northcott et al., 2012a; . Recently, a more detailed classification based on gene transcription profile, DNA copy number alterations, and DNA methylation pattern has been proposed that further divides medulloblastoma into 12 subgroups (two WNT, four SHH, three Group 3, and three Group 4 subgroups) (Cavalli et al., 2017) . However, the exact molecular basis of each subgroup is still under intensive investigation. The improved understanding of medulloblastoma tumor biology may enable personalized targeted therapy, preventing the overtreatment of some medulloblastoma patients and developing new treatment for the more aggressive subgroups.
WNT subgroup
The WNT subgroup accounts for about 10% of medulloblastoma patients (M.D. . The WNT α type tumors mainly occur in children, whereas WNT β occurs in adults (Cavalli et al., 2017) . These tumors appear to arise from the lower rhombic lip and often develop in a central location (Gibson et al., 2010) . Most WNT medulloblastomas contain activating CTNNB1 mutations and display activated WNT signaling. DDX3X, which encodes an ATP-dependent RNA helicase, has mutations enriched in but not exclusive to the WNT subtype Northcott et al., 2012c; Parsons et al., 2011; Pugh et al., 2012; Robinson et al., 2012) . TP53 mutations are identified in approximately 15% of WNT medulloblastomas but are not associated with poor prognosis (Zhukova et al., 2013) . It remains unclear how DDX3X and TP53 mutations function in tumorigenesis in this subtype. Patients with WNT medulloblastoma have the best prognosis and survival among the four main subgroups (Ellison et al., 2005) . development. Mutations causing constitutively active SHH signaling and increased downstream target gene expression are drivers of SHH medulloblastoma (Barakat et al., 2010; Kool et al., 2014) . Most SHH medulloblastomas contain mutations or deletions of SHH pathway genes such as PTCH1, SMO, or SUFU or amplifications of downstream transcription activators GLI1 or GLI2 . SHH medulloblastomas are grouped into four subcategories that occur in infants (< 4 years, SHH β and SHH γ), children (4 to 17 years, SHH α), and adults (> 17 years, SHH δ) (Cavalli et al., 2017; Kool et al., 2014) . Infant SHH γ medulloblastoma patients have excellent prognosis when treated with chemotherapy alone, whereas infant patients with SHH β tumors often suffer metastases and have poor prognosis. About half of the SHH α childhood medulloblastomas contain TP53 mutations. These patients have the worst outcome. Patients with adult or childhood SHH medulloblastoma with wild-type TP53 have intermediate prognosis Kool et al., 2012) . Interestingly, mutations in TERT (telomerase reverse transcriptase) promoters are highly enriched in SHH δ medulloblastoma, and these mutations are associated with better treatment outcomes within this group (Cavalli et al., 2017; ).
Group 3
Group 3 represents roughly 25% of medulloblastoma occurrences. It occurs more commonly in males than females and is found in infants and children. The most frequently mutated gene is SMARCA4 (11%), which encodes a chromatin remodeling factor. Almost half of Group 3 patients are in Group 3α. The amplification of a homeobox gene OTX2 and enhancer hijacking for GFI1/GFI1B, which juxtapose GFI1 or GFI1B coding sequences proximal to active enhancer elements, are enriched in Group 3β medulloblastoma (Cavalli et al., 2017; . MYC amplification is highly associated with Group 3γ medulloblastoma. Group 3γ medulloblastoma patients have high rates of metastasis and poor treatment outcomes with < 50% 5-year survival rates, whereas other Group 3 patients have intermediate survival rates (Cavalli et al., 2017; .
Group 4
Group 4 tumors account for > 35% of all occurrences and are the most prevalent among all medulloblastoma subgroups. The molecular pathogenesis of Group 4 medulloblastoma remains unclear. These tumors share some similarities with Group 3 medulloblastoma but with few MYC amplifications. Some Group 4 medulloblastomas also harbor OTX2 amplifications and enhancer hijacking of GFI1/GFI1B albeit with lower percentages than Group 3 medulloblastoma (Cavalli et al., 2017; . One prominent feature of Group 4 medulloblastoma is that approximately 80% of these patients have isochromosome 17q (Shih et al., 2014) . KCNA1 has been suggested as an immunohistochemical marker for Group 4 tumors, and genes involved in neuronal differentiation and development are overrepresented in Group 4 medulloblastoma transcription profiles (M.D. . Group 4α tumors are enriched for MYCN amplifications, and Group 4β are strongly enriched for SNCAIP duplications. Groups 4α and 4γ are enriched for focal CDK6 amplifications (Cavalli et al., 2017) . One of the frequently mutated genes in Group 4 tumors encodes the H3K27me3 demethylase KDM6A/UTX . Group 4 medulloblastoma occurs most often in children between 6 and 8 years old and with a high male preponderance. Female patients with Group 4 medulloblastoma have high incidence of X chromosome loss in tumor tissues (Shih et al., 2014) . The overall therapeutic outcomes of patients with Group 4 medulloblastoma are intermediate.
Epigenetic alterations associated with human medulloblastoma subgroups
Epigenetic regulation plays important roles in cancer development with alterations identified in many cancers with high frequency (Feinberg et al., 2016; Jones et al., 2016) . One of the most intriguing discoveries from the genomic studies of medulloblastoma is the high rate of alterations of epigenetic regulators across all four subgroups (Table 1) . > 30% of medulloblastoma samples harbor mutations, deletions, or amplifications of genes encoding epigenetic regulators. Each medulloblastoma subtype also displays common and distinct epigenetic properties (Batora et al., 2014; Dubuc et al., 2013; Jones et al., 2013) . This finding suggests that epigenetic alterations may be important drivers of medulloblastoma. Although the functions of epigenetic factors are not restricted to transcription regulation, it is speculated that in cancer these factors regulate expression of genes that drive cancer progression. The generation and the maintenance of the transcription programs specifically required for each medulloblastoma subtype may require different sets of chromatin remodelers and histone modifiers. In this review, we will mainly focus on three types of epigenetic regulation in medulloblastoma: DNA methylation, histone modifications, and ATPdependent chromatin remodeling. One common feature of these epigenetic regulators is their diverse and context-dependent functions in cancers. Epigenetic regulators can function as tumor suppressors or oncogenes, possibly depending on the gene program regulated by these factors and the gene programs required for tumor growth. The possibility of inhibiting enzymatic activities of epigenetic regulators has put these factors in the spotlight as candidate drug targets for treatment of medulloblastoma. Due to the highly context-dependent and subgroupspecific functions of epigenetic regulators, treatments will need to be personalized.
DNA methylation
Alteration of DNA methylation is a common feature of tumorigenesis (Jones and Baylin, 2007) . Repression of candidate tumor suppressors by promoter CpG island hypermethylation was studied in medulloblastoma before the genome era. Using several assays for methylated DNA, including bisulfite sequencing of specific regions, a number of candidate tumor suppressors were identified that are silenced in medulloblastoma by promoter hypermethylation; these include PTCH1 and ZIC2 (Diede et al., 2010; Pfister et al., 2007) . Treatment of medulloblastoma cancer cell lines with DNA methylation inhibitors also resulted in identification of genes with expression increased by the inhibitors (reviewed in (Batora et al., 2014) ). In these studies, however, the tumor samples used were not subgroup classified, and some studies were not properly controlled using cells of origin for specific medulloblastomas.
Recent genome-wide studies of DNA methylation patterns in subgroup classified medulloblastoma have provided new insights into the tumor molecular pathogenesis. Using DNA methylation microarrays, DNA methylation status at 1505 loci in 807 genes was analyzed in 230 medulloblastoma samples previously classified with transcription profiles. The four subgroups identified based on DNA methylation are highly related to their transcriptome counterparts, suggesting that each medulloblastoma subgroup has a specific DNA methylation pattern which can be used as a robust subclassification standard . By comparing DNA methylation in both mouse and human medulloblastoma, an oncogene VAV1 was found hypomethylated with elevated expression in most human SHH medulloblastoma and mouse SHH medulloblastoma models. Manipulation of VAV1 levels in medulloblastoma models showed that VAV1 is important for tumor maintenance (Lindsey et al., 2015) .
In another whole-genome bisulfite sequencing analysis, Hovestadt et al. compared 34 human and five mouse medulloblastoma samples plus proper human and mouse normal controls. The bisulfite sequencing analysis together with matched RNA-seq and ChIP-seq data provided a comprehensive view of the DNA methylation landscape and gene expression profiles . The authors found that the classical notion of gene silencing through promoter hypermethylation was not a prominent feature in medulloblastoma. Instead, there is a high incident of hypomethylation of the region downstream of promoters extending tens of kilobases into the gene body, and this correlates with increased gene expression. Focal regions of low methylation are linked to transcription factor binding sites that may specify different transcription networks in different medulloblastoma subgroups. Differential methylation around the LIN28B gene suggested use of an alternate promoter in Group 3 and Group 4 tumors, which may result in higher levels of LIN28B and more aggressive tumor growth . Notably, DNA methylation in tumors can be inherited from their cell-of-origin neural lineages but also can be generated de novo in tumors. It is not clear how these cancer-specific DNA methylation alterations are regulated by changes of the activities of DNA methyltransferases and/or enzymes that remove the methyl groups.
Histone modifications
Histone modifications such as acetylation, methylation, phosphorylation, and ubiquitination may either alter local chromatin structures or, more importantly, recruit proteins (readers) that recognize the modifications and regulate gene transcription. Multiple genes encoding histone modification enzymes or readers are altered in medulloblastoma, most with specific subgroup bias. An early study of DNA copy number alterations provided strong evidence that many epigenetic regulators are affected in medulloblastoma (Northcott et al., 2009) . Recurrent focal amplifications and homozygous deletions in genes targeting histone lysine methylation, particularly that of H3K9, were identified. These include genes encoding the methyltransferases EHMT1 and SMYD4, polycomb proteins L3MBTL3, L3MBTL2, and SCML2, and histone demethylases JMJD2C and JMJD2B. Consistent with this finding, approximately 40% of medulloblastoma samples display lower than normal global H3K9me3. A recent more comprehensive study analyzing > 1000 medulloblastoma samples confirmed the importance of the copy number changes of histone modification enzymes in medulloblastoma (Northcott et al., 2012c) . However, it remains largely unclear how these epigenetic changes impact medulloblastoma development.
Dysregulated chromatin regulation pathways identified through genome-wide sequencing of medulloblastoma involve H3K4 and H3K27 methylation. The genes encoding H3K4 methyltransferases MLL2/ KMT2D and MLL3/KMT2C are mutated in about 8% and 3% of medulloblastomas independent of subgroups. MLL2/3 complexes are required to maintain levels of H3K4me1, which marks enhancers (Rao and Dou, 2015; Sze and Shilatifard, 2016) . MLL2/3 may activate gene expression through modulating enhancer activities during development and in cancer. UTX/KDM6A mutations and homozygous deletions are identified in 4% of medulloblastoma and are enriched in Group 4 tumors. In addition, Group 4 medulloblastoma patients are generally male, and tumors in female patients have often lost one X chromosome, where UTX is located Jones et al., 2013) . UTX activates genes by demethylating the repressive H3K27me3 mark. Interestingly, UTX interacts tightly with MLL2/3 complexes and is considered a subunit of these complexes (Cho et al., 2007; Lee et al., 2007) . Together they may activate genes by methylating H3K4 and removing H3K27me3. Therefore, MLL2/3 and UTX mutations are largely mutually exclusive in medulloblastoma ; however, the pan-medulloblastoma mutation pattern of MLL2/3 indicates its additional role in non-Group 4 medulloblastoma.
In line with the mutations of UTX in Group 4 medulloblastoma, EZH2, EED, and SUZ12 subunits of the H3K27 methyltransferase PRC2 complex, are highly expressed, and the genes encoding these factors are often amplified in medulloblastoma (Bunt et al., 2013; Dubuc et al., 2013) . In many cancers, PRC2 subunits function as oncogenes. Overexpression and gain-of-function mutations of PRC2 were observed in many cancers, which may result in a high level of H3K27me3 (Greer and Shi, 2012; Hock, 2012; Martinez-Garcia and Licht, 2010) . PRC2 may repress specific tumor suppressor genes and facilitate cancer development. Notably, however, some cancers are associated with PRC2 loss-of-function mutations and low levels of H3K27me3 (Hock, 2012; Simon and Lange, 2008) , which drives the expression of specific oncogenes (Chan et al., 2013; Lewis et al., 2013; Schwartzentruber et al., 2012; Wu et al., 2012a) . Group 3 and Group 4 medulloblastoma have relatively high global H3K27me3 levels . Within Group 3 and Group 4 tumors, a global high H3K4me3 and low H3K27me3 status is associated with better prognosis than low levels of both H3K4me3 and H3K27me3 . However, a recent genetic study indicated a tumor suppressor function of EZH2 in a mouse Group 3 medulloblastoma model (discussed further below) (Vo et al., 2017) . The tumor suppressor functions of MLL2/3 and UTX have not yet been verified in mouse models or human medulloblastoma xenografts.
In addition to histone methylation modifiers, histone acetyltransferases (HATs) and deactylases (HDACs) also play important and context-dependent roles in medulloblastoma. hMOF, a HAT for H4K16, has been shown to be down regulated in many medulloblastoma samples, and this down regulation is associated with low rates of survival (Pfister et al., 2008) . The HAT genes that are mutated in some medulloblastoma patients are CREBBP and EP300 Pugh et al., 2012; Robinson et al., 2012) ; these genes encode CBP and p300, respectively, enzymes that catalyze H3K27Ac. H3K27Ac is a marker for active enhancers, and the HATs CBP and p300 activate the expression of many genes important for development and cancer progression (Jin et al., 2011; Ong and Corces, 2011) . Although the target genes of CBP and p300 remain unclear in medulloblastoma, a genome-wide enhancer and super-enhancer study using H3K27Ac ChIP-seq revealed subgroup specific cis-regulatory element landscapes (Lin et al., 2016) . Importantly, the analyses of super-enhancer regulated transcription factors suggest LMX1a as a master regulator in both cerebellum upper rhombic lip and in Group 4 medulloblastoma. The neural precursors derived from upper rhombic lip are putative cells of origin for Group 4 tumors. In general, HDACs likely support medulloblastoma growth, and HDAC inhibitors are being tested in clinical trials for treatment of medulloblastoma (see below). In SHH medulloblastoma, however, genes encoding several members of a nuclear receptor corepressor (NCoR) complex, which is associated with HDACs to repress gene expression, were found to be mutated , suggesting an inhibiting role of this complex in SHH medulloblastoma.
ATP-dependent chromatin remodeling
ATP-dependent chromatin remodeling complexes regulate chromatin structure using energy derived from ATP hydrolysis. The prototypical complex, the SWI/SNF-like BAF complex, containing 10-12 tightly associated subunits, can function as a transcription repressor and activator and is important for many developmental processes (Hargreaves and Crabtree, 2011; Wu, 2012) . Recent genomic studies showed that genes encoding BAF complex subunits were mutated in > 20% of all cancers, making them among the most mutated genes in cancer (Kadoch et al., 2013; Wilson and Roberts, 2011; Wu, 2012) . The functions of these ATP-dependent chromatin remodeling complexes in cancers appear to be highly context-dependent. Various signaling pathways and cancer-related genes were identified as targets of Brg1/SMARCA4, a BAF complex core ATPase subunit, in different cancers, which may contribute to its potential tumor suppressor functions. BAF complexes are abundant in the nucleus, but effects are dose sensitive. Heterozygous missense mutations as well as homozygous deletions in genes encoding BAF complex subunits are observed in different type of cancers (Kadoch et al., 2013) . Different mechanisms may contribute to cancer growth, which are under intensive investigation. Interestingly, in certain cancers, genes encoding BAF subunits are not mutated and are even required for oncogenesis (Romero et al., 2014; Shi et al., 2013) . In addition to chromatin remodeling activities, BAF complexes interact with many other chromatin regulators. BAF complexes functionally antagonize polycomb repressive complexes (PRC1 and PRC2) under specific conditions Stanton et al., 2017) . In atypical rhabdoid tumors (ATRTs), where mutations of BAF subunit genes are the main oncogenic cause, PRC2 activities are increased (Wilson et al., 2010) . Inactivating PRC2 activities has been pursued as a treatment strategy for ATRT and other cancers with BAF subunit mutations (Kim et al., 2015) , but currently there are no effective BAF inhibitors.
In medulloblastoma, mutations in genes encoding BAF subunits such as Brg1 and ARID1A are among the most frequently observed in WNT and Group 3 tumors, with 25% and 11% having these mutations, respectively Parsons et al., 2011; Pugh et al., 2012; Robinson et al., 2012) . The missense mutations of Brg1 are mostly located in the ATPase domain and have been shown to affect the interaction with topoisomerase 1a (Dykhuizen et al., 2013) . The expression of Brg1 with point mutations identified in medulloblastoma leads to anaphase bridge formation and a G 2 /M phase block characteristic of the decatenation checkpoint. It remains unclear whether this defect contributes to medulloblastoma pathogenesis. In SHH and Group 4 medulloblastoma, Brg1 is largely free of mutations, suggesting an essential function of Brg1 in tumorigenesis. Our study of Brg1 function in SHH medulloblastoma revealed a key function of Brg1 in coordinating a genetic and epigenetic network supporting SHH medulloblastoma proliferation and identity (discussed below) (Shi et al., 2016) . Interestingly, although mutations in genes encoding other BAF subunits are rare in pediatric SHH medulloblastoma, they are present in adult SHH medulloblastoma . It is not clear how these mutations regulate adult tumor progression; they may contribute to the tumor heterogeneity between pediatric and adult medulloblastoma.
In addition to BAF subunits, mutations in CHD7, which encodes another chromatin remodeler, were identified in Group 3 and Group 4 medulloblastoma . Germline mutations in CHD7 cause CHARGE syndrome, a multiple anomaly condition with defects in the nervous system (Martin, 2015) . Medulloblastoma has been reported in CHARGE syndrome patients . Similarly, germline mutations in several chromatin regulators cause multi-system developmental diseases. For example, CREBBP mutation is the genetic cause of Rubinstein-Taybi Syndrome (Petrij et al., 1995) , and these patients are predisposed to medulloblastoma Skousen et al., 1996) . Mutations in BAF subunits cause Coffin-Siris syndrome (Santen et al., 2012; Tsurusaki et al., 2012) . MLL2 or UTX mutations cause Kabuki syndrome (Miyake et al., 2013) . It remains unclear whether Coffin-Siris and Kabuki patients are predisposed to medulloblastoma.
Functions of epigenetic regulators in medulloblastoma
The high frequency of alterations of epigenetic regulators in medulloblastoma suggests the importance of chromatin regulation in tumor pathogenesis. To determine functions of proteins in medulloblastoma initiation and progression, loss-of-function and gain-of-function analyses are essential (Table 1, Fig. 1 ). Since many medulloblastoma cell lines do not closely recapitulate tumor properties in culture, here we will focus on the studies using mouse models and patient-derived xenografts. Several genetically modified mouse lines develop medulloblastomas that resemble specific human subgroups. The Blbp-cre Ctnnb1(ex3) Fl/+ TP53 Fl/+ mice express active β-catenin proteins in hindbrain germinal zones and develop medulloblastoma at the dorsal brainstem region. These tumors resemble WNT subtype (Gibson et al., 2010) . A number of strains harboring mutations in SHH pathway genes such as PTCH1, SMO or SUFU produce medulloblastomas resembling SHH-type, albeit more similar to the adult subtype than the infant ones . Recently, Group 3 mouse models were generated by overexpression of MYC in TP53-deficient CGNPs or cerebellum neural stem cells (Kawauchi et al., 2017; Kawauchi et al., 2012; Pei et al., 2012) . No mouse model for Group 4 medulloblastoma has been generated. Several lines of patient-derived medulloblastoma xenografts have been generated that maintain the molecular fidelity of primary tumors and are useful for genetic or pharmacological studies of medulloblastoma (Dietl et al., 2016; Milde et al., 2012; Zhao et al., 2012) . Notably, genetic mutations of most epigenetic regulators alone cause developmental defects but rarely produce tumors in mice. Therefore, these epigenetic regulators may need to cooperate with other cancer gene alterations to facilitate tumor development. The spatial and temporal manipulations of the epigenetic regulators also need to be well controlled in order to cause relevant context-dependent functions in tumor development.
Epigenetic regulation in SHH signaling and SHH medulloblastoma
SHH medulloblastoma is more extensively studied than other subgroups, mainly due to our good understanding of the SHH signaling pathway and the availability of several SHH medulloblastoma mouse models. SHH signaling regulates development and cancer by modulating the activities of GLI family transcription factors. SHH activation releases inhibition of SMO by PTCH1 to activate GLI1/2 transcription activators and downstream target gene expression (Briscoe and Therond, 2013; Fuccillo et al., 2006; Ingham and McMahon, 2001; Jiang and Hui, 2008 ). An active SHH signaling pathway is required for the proliferation of CGNPs, the cells of origin of SHH medulloblastoma (Gibson et al., 2010) . Mutations that result in constitutively active SHH signaling cause over proliferation of CGNP and are the essential genetic causes of SHH medulloblastoma (Barakat et al., 2010; Kool et al., 2014) .
GLI-mediated gene activation is the downstream executive step of SHH signaling and is an attractive treatment target for SHH medulloblastoma. In recent years, the epigenetic mechanism regulating GLI mediated gene transcription has begun to be characterized (Fig. 1A) . Our early work demonstrated that the chromatin remodeler Brg1 plays a dual role in SHH signaling by both repressing the GLI3R-mediated basal expression and activating GLI1/2-mediated target gene activation (Zhan et al., 2011) . Conditional Brg1 deletion in cerebellum leads to decreased expression of SHH/GLI target genes and reduced CGNP proliferation, resulting in smaller cerebellum (Moreno et al., 2014; Shi et al., 2016) . In a SMO-induced medulloblastoma model, reducing Brg1 dose or deleting Brg1 in CGNPs impaired medulloblastoma initiation, and deleting Brg1 after tumor formation significantly reduced tumor cell proliferation and growth (Shi et al., 2016) .
Gene expression and Brg1 ChIP-seq analyses revealed a central role of Brg1 in regulating the key transcription pathways that control medulloblastoma proliferation and identity. In addition to the mitogenic SHH/GLI target genes, Brg1 also activates the target genes of ATOH1, a master regulator of CGNP and SHH medulloblastoma identity. Brg1 is also required for repression of a large number of neuronal genes that are targets of a master repressor REST/NRSF. By activating the GLI and ATOH1 oncogenic activities and repressing neuron differentiation, Brg1 coordinates a transcription network underlying SHH medulloblastoma proliferation and identity. In human SHH medulloblastoma, these transcription pathways are also over-represented and likely play key roles in tumor development (Shi et al., 2016) . In addition to the chromatin remodelers, histone modification enzymes also play important roles in regulating SHH/GLI-mediated target gene expression and SHH medulloblastoma. An examination of histone modifications of SHH target genes revealed that these genes all have H3K4me3/H3K27me3 bivalent chromatin domains at their regulatory regions (Shi et al., 2014) . These bivalent domains keep the target genes at poised states under basal conditions. PRC2 complex is required to maintain the H3K27me3 levels and basal repression of target genes. SHH stimulation induces an exchange of epigenetic regulator complexes from the repressive PRC2 to a GLI1/2 interacting co-activator complex containing an H3K27me3 demethylase JMJD3/KDM6b, H3K4 methyltransferase MLL/SET complex, and BAF complexes (Fig. 1A) . In response to SHH activation, JMJD3 replaces PRC2, removes H3K27me3 repressive marks, and recruits other co-activators such as MLL complex. JMJD3 deletion in mice led to impaired SHH-dependent developmental processes and resulted, for example, in smaller cerebella. Further, JMJD3 inhibition reduces proliferation and growth of SMO-induced medulloblastoma ( (Shi et al., 2014) These co-repressors include HDACs, LSD1/KDM1A and G9A. G9A also mediates the repression of a tumor suppressor USP37 by REST. USP37 stabilizes p27/CDKN1B by deubiquitination (-Ub).
2010; Shi et al., 2014) . This paradox indicates the presence of and possibly the requirement for high H3K27me3 demethylase activities in SHH medulloblastoma. In SMO-induced medulloblastoma, Brg1 deletion impairs tumor growth, which correlates with increased global H3K27me3 and reduced JMJD3 binding to SHH target genes (Shi et al., 2016) . Therefore, a complex epigenetic network comprising chromatin remodelers and histone modifiers function together with GLI activators to produce specific transcription outcomes supporting SHH medulloblastoma growth (Fig. 1A) . GSK-J4, an inhibitor of H3K27me3 demethylases JMJD3 and UTX, inhibits cancer growth (Hashizume et al., 2014; Kruidenier et al., 2012; Ntziachristos et al., 2014) . However, since it inhibits both JMJD3 and UTX and these factors may play opposite roles in medulloblastoma growth (Yi et al., unpublished data) , it will be of interest to evaluate the effect of GSK-J4 on medulloblastoma development.
In an RNAi screen for HATs that affect SHH/GLI-induced gene activation, PCAF/KAT2B was identified (Malatesta et al., 2013) . PCAF depletion impairs SHH activity and reduces expression of SHH target genes. PCAF downregulation in medulloblastoma and glioblastoma cells leads to decreased proliferation and increased apoptosis. PCAF interacts with GLI1 and possibly regulates gene expression by affecting local H3K9Ac levels. PCAF silencing reduces the glioma-forming potential of neural stem cells in a mouse xenograft model. However, in another study, PCAF was shown to be elevated by p53 and to represses SHH signaling in response to DNA damage by ubiquitinating and destabilizing GLI1 through its ubiquitin ligase activity (Mazza et al., 2013) . DNA-damaging agents fail to inhibit GLI1 activity in the absence of either p53 or PCAF. Medulloblastoma samples from TP53-null mice display low levels of PCAF and upregulated GLI1. Therefore, inhibiting PCAF in SHH medulloblastoma may lead to complex consequences.
Class I HDACs such as HDAC1 have been shown to enhance GLI1/2 activities by deacetylating GLI1 and GLI2 (Canettieri et al., 2010; Coni et al., 2013) . Activation of SHH signaling increases HDAC1 levels, leading to GLI1/2 deacetylation and activation. A ubiquitinase complex REN-CUL3 represses GLI activities by ubiquitinating and degrading HDAC1. HDAC1 inhibition impairs CGNP proliferation and the growth of medulloblastoma cell lines (Canettieri et al., 2010) . Interestingly, we have shown that Brg1 facilitates class I HDAC2 binding to GLI target genes and functions in conjunction with HDACs to activate SHH target genes (Zhan et al., 2011) . It remains unclear how HDACs selectively deacetylate GLI1/2 in regulatory regions but not histones.
EZH2 function in MYC-driven Group 3 medulloblastoma
The recent generation of mouse Group 3 medulloblastoma models has enabled functional studies of epigenetic regulators in this type of aggressive tumor Pei et al., 2012) . The overexpression of PRC2 complexes, mutations in UTX and the globally high H3K27me3 in Groups 3 and 4 medulloblastomas, together with the oncogenic function of PRC2 in other cancers, suggest that PRC2 subunit EZH2 may promote the development of Group 3 and Group 4 medulloblastoma. It was reported that EZH2 deficiency and EZH2 inhibitor treatment decrease medulloblastoma growth and inhibit tumor sphere formation in vitro (Alimova et al., 2012) . Liu et al. explored the interaction between EZH2 and MELK and found that both are essential for maintenance of the medulloblastoma cancer stem cell (MBSC) state and that disruption of expression of either factor results in the inhibition of MBSC activity (Liu et al., 2017) . EZH2 was also shown to repress the expression of DAB2IP, which may function as a tumor suppressor gene in many cancers including medulloblastoma (Smits et al., 2012) .
Most of these studies used cultured medulloblastoma cell lines, and a recent genetic study using the newly generated mouse MYC-driven Group 3 medulloblastoma model demonstrated a surprising tumor suppressor function of EZH2 (Vo et al., 2017) . In this medulloblastoma model with MYC overexpression and TP53 deletion, deleting EZH2 before or after tumor formation accelerated medulloblastoma development. The authors also showed that the Group 3/4-specific oncogene GFI1 was repressed by EZH2 (Fig. 1B) . Further, in the mouse model, overexpression of GFI1 together with MYC bypassed the need for TP53 deletion to induce medulloblastoma formation.
These studies demonstrate the complex function of epigenetic regulators in tumor development. These factors may regulate both oncogenes and tumor suppressors and the overall effects on tumorigenesis depend on the balance between these seemingly counteracting activities. Therefore mouse models and human xenografts are essential to evaluate the function of epigenetic factors, and these pleiotropic factors may not be appropriate as general treatment targets for all medulloblastoma subgroups.
Epigenetic regulators of multiple medulloblastoma subgroups
In addition to the functions in specific medulloblastoma subgroups, several epigenetic regulators appear to regulate multiple subtypes. PRC1 subunit BMI1 has been shown to be required for stem cell maintenance for a number of cancers (Lessard and Sauvageau, 2003; Valk-Lingbeek et al., 2004) . BMI1 binds to the promoter of the p16 ink4a / p19 Arf locus and represses the expression of these tumor suppressors (Lessard and Sauvageau, 2003) . BMI1 is expressed in CGNPs and overexpressed in medulloblastoma across subgroups. A high level of BMI1 expression is associated with poor prognosis (Leung et al., 2004; Manoranjan et al., 2013; Zakrzewska et al., 2011) . In SHH medulloblastoma, BMI1 regulates tumor growth through a mechanism that does not involve regulation of GLI-mediated transcription (Fig. 1C) . Deleting BMI1 causes reduced cerebellum size and impaired cerebellum development (Leung et al., 2004) . RNAi-mediated inhibition of BMI1 in human medulloblastoma DAOY cells results in the inhibition of growth. Deletion of BMI1 in a SMO-induced medulloblastoma mouse model blocked tumor expansion (Michael et al., 2008) . Transcriptome analyses of BMI1-null cerebellum showed that BMI1 regulates genes involved in the TGFβ signaling pathway, ECM remodeling and cell adhesion, and particularly, cell cycle control. BMI1 not only represses the well-characterized cell cycle inhibitors p16 Ink4a and p19 Arf but also p21 Waf1/Cip1 (Subkhankulova et al., 2010) . In addition, a PRC1 complex containing BMI1 binds p53 directly, promoting its ubiquitination and possibly degradation. BMI1-mediated p53 inactivation may abrogate the oncoprotein stress response at medulloblastoma initiation (Calao et al., 2013) . BMI1 expression is increased by SHH, possibly by direct GLI1 activation . In addition, BMI1 is repressed by microRNA Mir128a (Venkataraman et al., 2010) . Overexpression of BMI1 alone in CGNPs did not induce medulloblastoma, but reduced CGNP proliferation instead. However, in combination with TP53 deletion, overexpression of BMI1 causes low incidence of the formation of medulloblastoma (Behesti et al., 2013) . Although most of the functional studies of BMI1 have focused on SHH medulloblastoma, a recent genomic study showed that BMI1 expression is higher in Group 3 and Group 4 than in SHH group tumors and is the highest in Group 4 medulloblastoma. Using a xenograft model of Group 4 medulloblastoma and in vitro assays, the Marino group showed that BMI1 represses BMP signaling and the expression of cell adhesion genes (Merve et al., 2014) . BMI1 deletion in the xenograft medulloblastoma model affected both tumor volume and parenchymal invasion (Merve et al., 2014) (Fig. 1C) . The study of BMI1 may help us further understand the Group 4 medulloblastoma, which could also lead to the generation of mouse models for this least understood medulloblastoma subgroup.
REST/NRSF is a master regulator that represses expression of neuronal genes in non-neural cells and neural progenitors (Chong et al., 1995; Schoenherr and Anderson, 1995) . REST represses gene expression by incorporating multiple epigenetic co-repressors such as H3K9 methyltransferase G9A, HDACs, and H3K4 demethylase KDM1A/LSD1 (Ballas and Mandel, 2005; Ooi and Wood, 2007) . REST has been shown to function as a tumor suppressor in non-neural cancers and as an oncogene in neural tumors (Negrini et al., 2013) . REST is highly expressed in medulloblastoma. Expression of REST-VP16, an activator of REST target genes, induced neuronal gene expression and inhibited proliferation and growth of medulloblastoma cell lines and xenograft models (Lawinger et al., 2000) . Forced overexpression of REST together with MYC in cultured cerebellum neural stem cells blocks neuron differentiation. When injected into cerebellum, neural stem cells overexpressing REST and MYC grow into medulloblastoma . It will be interesting to see whether these tumors recapitulate certain Group 3 medulloblastoma phenotypes.
A more recent study showed that higher expression of REST in human medulloblastoma is associated with poor prognosis (P. . HDAC inhibitors as well as a KDM1A inhibitor both inhibit growth of medulloblastoma cell lines (Pajtler et al., 2013; . Inhibition of KDM1A-mediated demethylation of H3K4 might therefore be a promising targeted therapy approach. In addition to neuronal genes, the Gopalakrishnan group showed that REST represses the expression of a tumor suppressor USP37, which encodes a deubiquitinase that stabilizes p27/CDKN1B in cerebellum and medulloblastoma (Das et al., 2013; Dobson et al., 2017) . This repression is mediated through the interaction of REST with G9A and H3K9 methylation (Dobson et al., 2017) . Therefore REST may be an oncogene across the subgroups, and its associated epigenetic regulators could be targeted for medulloblastoma treatment (Fig. 1D) .
Three groups have used the powerful unbiased Sleeping Beauty transposon screen to identify candidate functional regulators that contribute to medulloblastoma development (Genovesi et al., 2013; Lastowska et al., 2013; Wu et al., 2012b) . Using the PTCH1 ± mouse model of SHH medulloblastoma, the three groups all identified additional factors whose alteration by transposons accelerated tumor growth. Most of the factors identified from these studies are involved in transcription regulation including several epigenetic regulators such as CREBBP, KDM1A, and BRD4 that were previously identified from human genome-wide sequencing analyses or other studies. Interestingly, although the original tumors generated in PTCH1 ± mice are SHH medulloblastoma, tumors induced by PTCH1 ± and transposon insertions resemble all four subgroups (Genovesi et al., 2013) , suggesting that changes in specific sets of key regulators, especially transcription factors and epigenetic regulators, may reprogram CGNPs to the cells of origin of other subgroups. Indeed, MYC overexpression in TP53 −/− CGNPs reprogram CGNPs into stem like cells and induce development into Group 3 medulloblastoma (Kawauchi et al., 2017) . Therefore although the four medulloblastoma subgroups display distinct transcription signatures and possibly have different cells of origins, specific common pathways may underlie the different medulloblastoma subgroups.
Epigenetic inhibitors for potential medulloblastoma treatment
The development of specific inhibitors of epigenetic regulators enables epigenetic therapy for targeted treatment of cancers and other diseases (Yoo and Jones, 2006) (Table 1) . For medulloblastoma treatment, brain penetrance is a challenge for drug development. For example, none of the EZH2 inhibitors so far developed cross the blood brain barrier (Zhang et al., 2015) . The brain penetrant DNA methylation inhibitors, HDAC inhibitors, and bromodomain inhibitors that have been tested in medulloblastoma models are discussed below. Combined treatments with inhibitors to other pathways are often used to increase the efficacy.
HDAC inhibitors
HDAC inhibitors have received considerable attention, and three HDAC inhibitors, vorinostat, romidepsin, and belinostat, have been approved by FDA to treat rare T cell lymphomas. Several clinical trials (e.g., NCT01294670 and NCT02780804) and many pre-clinical studies are ongoing to examine the effects of these inhibitors on medulloblastoma. Initial HDAC inhibitor studies showed that HDAC inhibition alone or in combination with other pathway inhibitors could effectively inhibit medulloblastoma cell proliferation in culture, induce cell death, and prolong xenografted mouse survival (Li et al., 2005; Shu et al., 2006; Wegener et al., 2008) . HDAC inhibitors and a tyrosine kinase inhibitor sorafenib synergize to kill central nervous system tumor cells (Tang et al., 2012) . Vorinostat and MLN8237 aurora kinase inhibitor have additive inhibition effects on medulloblastoma cell lines (Muscal et al., 2013) . Sodium butyrate inhibits survival of human medulloblastoma cells, and might potentiate the effects of etoposide in cancer cell killing (Nor et al., 2013) . In addition, panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model (Phi et al., 2017) .
HDAC inhibitors have been shown to affect SHH signaling and SHH medulloblastoma. As described earlier, HDACs may function as activators of transcription factors GLI1/2, and HDAC inhibitors appear to block GLI activities and SHH medulloblastoma growth (Canettieri et al., 2010) (Fig. 1A) . A comparison between normal cerebellum and SMOinduced medulloblastoma models showed increased expression of HDACs in medulloblastoma. Inhibition of HDACs ameliorates SMO-induced hyperplasia of CGNP cells during postnatal cerebellum development . Curcumin has been shown to induce apoptosis in medulloblastoma cells, and this is accompanied by reduced HDAC4 expression and increased tubulin acetylation. Curcumin treatment also displayed anti-tumor activity in a SMO-induced medulloblastoma model ).
An expression analyses of HDACs in human medulloblastoma samples revealed that genes encoding class IIa HDACs HDAC5 and HDAC9 showed the highest expression in prognostically poor subgroups. High HDAC5 and HDAC9 expression was significantly associated with poor overall survival. siRNA-mediated silencing of HDAC5 or HDAC9 in medulloblastoma cells results in decreased cell growth and cell viability. However, selective class IIa HDAC inhibitors did not inhibit medulloblastoma growth, suggesting that the enzymatic activity-independent functions of HDAC5 and HDAC9 may be important for medulloblastoma development (Milde et al., 2010) . The Milde group also developed a Group 3 medulloblastoma cell line and xenograft model that display high HDAC expression levels and growth sensitivity to HDAC inhibitors . Along the same line, inhibition of class I HDACs resulted in significant reductions in metabolic activity and proliferation of MYC-amplified medulloblastoma cells (Ecker et al., 2015) . HDAC inhibitors also emerged from a screen for small molecules that would selectively kill MYC-driven medulloblastoma cells but not normal cerebellum cells. HDAC inhibitors and PI3K inhibitors cooperate to activate FOXO1 and suppress MYC-driven tumors in vitro and in vivo (Pei et al., 2016) (Fig. 1B) .
Immunohistochemical staining of human medulloblastoma samples showed strong expression of SIRT1, a NAD-dependent deacetylase. SIRT1 inhibition by siRNA or nicotinamide causes growth arrest of medulloblastoma and apoptosis . Interestingly, a BCL6/BCOR/SIRT1 complex was identified as a potent repressor of the SHH pathway in normal and oncogenic neural development. SIRT1 is required for BCL6 function in repressing GLI1/2 expression. Inhibiting the complex activities promoted mouse SHH medulloblastoma growth and human medulloblastoma cell proliferation (Tiberi et al., 2014) (Fig. 1A) . These different results may reflect the cultured medulloblastoma cell differences or context-dependent function of SIRT1 in different medulloblastoma subgroups.
DNA methylation inhibitors
DNA methylation inhibitors have shown promising anticancer effects. 5-Azacytidine (5-aza-CR) and its variant 5-aza-2′-deoxycytidine (5-aza-CdR) are approved for the treatment of high-risk myelodysplastic syndrome. These inhibitors have been tested for use in combination with other drugs. The combination of 5-aza-CdR and valproic acid to inhibit HDACs reduces medulloblastoma initiation in PTCH1 mutant mice; however, it has little effect on advanced tumors in these mice (Ecke et al., 2009) . Another study showed that although 5-aza-CdR alone has minor effects on medulloblastoma cell growth, its combination with tyrosine kinase inhibitor Gleevec has significantly enhanced cytotoxicity. The HDAC inhibitor 4-phenylbutyrate (4-PB) in combination with 5-aza-CdR and Gleevec treatment reduces global methylation and induction of apoptosis . Another DNA methylation inhibitor zebularine shows low toxicity and high efficacy and is a promising adjuvant agent for anti-cancer chemotherapy. Zebularine inhibits proliferation and clonogenicity of melanoma cell lines and increases the apoptosis rate. In addition to the repression of expression of TP53 and other tumor suppressors, zebularine also inhibits expression of SHH pathway components such as SMO and GLI1. In addition, the combinations of zebularine with the chemotherapeutic agents vincristine and cisplatin result in synergism and antagonism, respectively (Andrade et al., 2017) .
Bromodomain inhibitors
Bromodomain inhibitors, especially those that inhibit the BET family proteins, have been tested extensively in vitro and in vivo for treating various cancers (Wadhwa and Nicolaides, 2016) . The BET family bromodomain proteins (BRD2, BRD3, BRD4) recognize acetyl-lysine and acetylated chromatin, which usually mark active enhancers. BET proteins function as principal mediators of gene activation. The super enhancers that regulate key genes in cancer growth are marked by high levels of H3K27Ac and are especially sensitive to BET inhibition (Loven et al., 2013) . These brain penetrant inhibitors are promising drugs for treatment of brain tumors including medulloblastoma. Several BET inhibitors, including the most extensively tested JQ-1, showed significant effects in both SHH and Group 3 medulloblastoma models.
BRD4 has been shown to regulate the GLI and SHH pathway activities. BRD4 inhibition by RNAi or the inhibitor JQ-1 reduces the expression of GLI1 and GLI2, resulting in decreased SHH medulloblastoma proliferation and tumor growth . Therefore, BET domain inhibitors are promising for treatment of SHH medulloblastomas that show resistance to SMO inhibitors. Another BET protein inhibitor, I-BET151, represses SHH/GLI reporter gene expression by reducing BRD4 binding to the GLI1 locus and inhibits the SHH pathway in a manner similar to BRD4 silencing. This inhibition significantly reduced the growth of allograft medulloblastoma derived from PT-CH1 ± mice (Long et al., 2014) (Fig. 1A) .
MYC amplification-induced cancers are very sensitive to BET inhibitors. Several studies have evaluated the effect of BET inhibitors in treating MYC-driven medulloblastoma. Henssen et al. found that treating medulloblastoma cell lines with BET inhibitors downregulated MYC and MYC target gene expression (Henssen et al., 2013) . Interestingly, BET inhibitors also deregulated genes involved in cell cycle and the p53 pathway. In a human Group 3 medulloblastoma xenograft model, JQ-1 treatment significantly prolongs host mouse survival and reduces tumor volumes (Henssen et al., 2013) . Bandopadhayay et al. showed that JQ-1 reduces the growth of medulloblastoma cell lines and inhibits the expression of MYC and MYCN and their downstream target genes and significantly reduces tumor growth and extends the survival of mice harboring medulloblastoma with MYC or MYCN overexpression . Similarly, Venkataraman et al. showed that JQ-1 treatment impairs the MYC-mediated transcription program and reduces MYC-driven medulloblastoma cell growth. In addition, they demonstrated that JQ-1 inhibits stem cell-associated signaling and induces cell senescence in culture and in a mouse xenograft model (Venkataraman et al., 2014) . Therefore, BET bromodomain inhibition is a promising therapeutic option for MYC-driven medulloblastoma (Fig. 1B) .
Conclusions and perspectives
The recent intense effort to determine medulloblastoma molecular genetics pathogenesis has the potential to enable use of precision medicine to treat medulloblastoma patients. Genetic and pharmacological studies of functions of epigenetic regulators in medulloblastoma initiation and progression in mouse models and patient-derived xenografts are keys to understanding the specific functions of these factors in the development of tumors of different medulloblastoma subgroups. The genome era is opening new frontiers for both pediatric oncologists and chromatin researchers. The demonstration that mutations in a large number of epigenetic regulators are involved in genetic diseases as well as pediatric malignancies provides new treatment opportunities and challenges at the same time. The enzymatic activities of epigenetic regulators are promising drug targets, whereas the pleiotropic functions of these factors in development and in cancers require caution for drug selection. More detailed tumor molecular genetics analyses, as well as functional analyses of epigenetic factors, will further the development of epigenetic therapies for medulloblastoma treatment.
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